With the recent passage of healthcare reform legislation, corporate consolidations, and a `get tough` policy at the FDA, it is difficult to tell what the commercial healthcare landscape will look like during the next five years. A distinguished panel of experts representing biopharmaceuticals, medical devices, and regulatory affairs, will discuss and presage the impact of this changing environment. They will answer your questions and provide an interesting, informative perspective on the challenges we will face in the future.